Michael A. Siem
Partner, Goldberg Segalla (www.goldbergsegalla.com)
Illinois Institute of Technology, B.S., Chemical Engineering, 1996
University of Michigan Law School, J.D., 2000
Michael Siem was previously a Principal at Fish & Richardson PC, the largest patent litigation firm in the United States; a Partner of Farney Daniels PC, a leading plaintiff’s patent litigation firm; and a Partner at Devlin Law. Mr. Siem’s practice includes intellectual property litigation with a focus on patents. Over the last several years, Mr. Siem has appeared before various federal district courts and litigated cases in many technological areas including pharmaceuticals, chemical processes and biotechnology. Mr. Siem’s practice has focused primarily on pharmaceutical litigation related to the HatchWaxman Act. In addition to his HatchWaxman practice, he has also litigated cases in various technologies including potential anticancer drugs, agriculture and medical devices. Mr. Siem’s practice includes representation of both patentees and alleged infringers. Mr. Siem’s experience encompasses every aspect of litigation, beginning with the presuit investigation and continuing through trial.
Mr. Siem has experience handling various pro bono matters. In 2010 Mr. Siem obtained a reversal and new sentencing hearing for his client in the Virginia Supreme Court. Mr. Siem was also lead counsel in a challenge to the constitutionality of lethal injection in the State of Georgia and obtained an indefinite stay of execution on October 18, 2007 for his client. Mr. Siem was a recipient of the 2008 Thurgood Marshall Award for Capital Representation given by the Committee on Capital Punishment of the Association of the Bar of the City of New York.
Novartis AG, Novartis Pharmaceuticals Corp., Mitsubishi Tanabe Pharma Corp., and Mitsui Sugar Co. Ltd. v. HEC Pharm Co., Ltd., HEC Pharm Group, and HEC Pharm USA Inc., Civil Action No. 1:15-cv-00151-LPS (D Del.). Mr. Siem is lead counsel for defendants in a Hatch-Waxman action over an ANDA filing concerning fingolimod used in the treatment of patients with relapsing forms of multiple sclerosis.
Cephalon, Inc., v. Nang Kuang Pharmaceutical Co., Ltd. and CANDA NK-1, LLC, Civil Action No. 1:14-cv-5180 SJ-RER (EDNY). Mr. Siem is lead counsel for defendants in a Hatch-Waxman action over an ANDA filing concerning bendamustine hydrochloride used in the treatment of patients with chronic lymphocytic leukemia
Eli Lilly and Company and The Trustees of Princeton University, v. Nang Kuang Pharmaceutical Co., Ltd. and CANDA NK-2, LLC, Civil Action No. 1:14-cv-1647-TWP-DKL (SD Ind.). Mr. Siem is counsel for defendants in a Hatch-Waxman action over an ANDA filing concerning pemetrexed used in the treatment of patients with advanced nonsquamous non-small cell lung cancer and malignant pleural mesothelioma.
D.J. Miller Music Distributors, Inc. v. Strauser et al.; Civil Action No. 0900897 (Middle District of Florida). Mr. Siem was lead counsel on behalf of D.J. Miller Music Distributors, Inc. in a trademark litigation under the Anticybersquatting Consumer Protection Act related to the use and registration of the domain name www.prosing.com. The case ended in a favorable settlement.